Análisis de la acción enGene Therapeutics Inc (ENGN)

Análisis de IA of enGene Therapeutics Inc (ENGN)

Vender

enGene Holdings Inc is not a good buy right now due to significant financial losses and negative analyst sentiment. The current price is $1.45, which is 88.2% below its 52-week high of $12.25, indicating a substantial decline. Additionally, the RSI is at 23.7, suggesting the stock is oversold, but this could reflect ongoing issues rather than a buying opportunity. The company reported a net loss of $30.23 million in Q2 2026, which is wider than the previous year's loss, and its forward P/E ratio is 0, indicating no expected earnings growth. The main risk is the recent downgrade by Morgan Stanley, which has reduced its price target to $1, reflecting low confidence in the company's future performance.

Métricas de valoración

El PER previsto actual de enGene Therapeutics Inc (ENGN) es 0.00, frente a su media de 5 años de -3.05.

PER previsto

Sobrevalorado

Media 5A P/E

-3.05

P/E actual

0.00

Sobrevalorada

-0.13

Infravalorada

-5.97

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-2.08

EV/EBITDA actual

0.00

Sobrevalorada

1.25

Infravalorada

-5.40

Precio/ventas previsto

Sobrevalorado

Media 5A P/S

4.30

P/S actual

20.60

Sobrevalorada

12.61

Infravalorada

-4.02

Escenarios de precio de Alphio AI para ENGN

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ENGN

$4.68

Precio del escenario

B

Base

Base · 50%ENGN

$4.26

Precio del escenario

B

Bajista

Bajista · 25%ENGN

$3.67

Precio del escenario

Ballenas con ENGN en cartera

N

Nextech Invest Ltd.

+ Con en carteraENGN

-1.90%

Rentabilidad a 3 meses

Preguntas frecuentes sobre ENGN, respondidas por Alphio AI

enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA). It operates in the Healthcare sector.

enGene Holdings Inc is not a good buy right now due to significant financial losses and negative analyst sentiment. The current price is $1.45, which is 88.2% below its 52-week high of $12.25, indicating a substantial decline. Additionally, the RSI is at 23.7, suggesting the stock is oversold, but this could reflect ongoing issues rather than a buying opportunity. The company reported a net loss of $30.23 million in Q2 2026, which is wider than the previous year's loss, and its forward P/E ratio is 0, indicating no expected earnings growth. The main risk is the recent downgrade by Morgan Stanley, which has reduced its price target to $1, reflecting low confidence in the company's future performance.